Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Because they don't know how to support their stock and fins where only marginally better then last time, which took us down to the 52 week low, makes sense we will trade in that area until they get their shit togethere
$RGDX 1.19 nearing offering levels again!
Thx sir
Litterally half of the stuff said in the cc could have been pr"d.
They don't update very well. Go look at sheffs posts that's why he left
hey man can you revise the fork? thx bro
The company doesn't know how to do proper ir. They
Keep investors in the dark and wait 3 months to inform people in cc.
Idiots but what can u do?
$RGDX 1.23 might be time to jump back in for another swing
Ditto man only up from here barring any bad press or share sales
its OKAY, better then last quarter but could be better still. think we are on the road to building back up.
for reals lol crossing fingers, if its bad we hit 125 if its medium we stay in the 140-150 range and if its good 160+
looks good, if earnings rock should be a nice resistance breaker
$RGDX warming up for earnings!!
Got it looks good ur right. Thanks
great thx, with earnings next week lets see what happens
im new to forks, can u explains to me please what im looking at here. (im in this stock)
Nice man I'm hoping for big things, I'll probably be holding thru next earnings or the following I think we see 2 buck chuck. Plus we reached the 3rd milestone payment so things are coming thru
$RGDX news out!
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer today announced the commercial availability of its expanded KRAS assay, a mutation detection test that provides broader coverage of KRAS mutations, including those in regions of the gene not previously examined.
KRAS mutation status is used to predict whether or not a patient will respond to anti-EGFR therapy, and assessing KRAS status is recommended in the NCCN guidelines for colorectal cancer. Recently, additional mutations in the KRAS gene were discovered in global, multicenter, randomized Phase 3 studies.1,2 These studies showed that in addition to the well-studied mutations in exon 2 that predict for lack of response to anti-EGFR therapy, mutations in exon 3 and exon 4 may be important for anti-EGFR therapy selection.
"As a company known for its first-to-market innovation, we are pleased to introduce a test that detects more mutations in a gene not examined previously, allowing for a more thorough and comprehensive screening of colorectal cancer," said Thomas A. Bologna, Chairman and Chief Executive Officer of Response Genetics. "Identifying a broader range of KRAS mutations increases the potential for more targeted and appropriate treatment of colorectal cancer patients."
Peeters M, Oliner KS, Parker A, et al. Massively-parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Ca Res. 2013; 19:1902-1912.
Douillard, JY, Oliner, KS, Siena, S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Eng Med. 2013; 369: 1023-34.
About Response Genetics, Inc.
Response Genetics, Inc. (the "Company") is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer. The Company's technologies enable extraction and analysis of genetic information derived from tumor cells stored as formalin-fixed and paraffin-embedded specimens. The Company's principal customers include oncologists and pathologists. In addition to diagnostic testing services, the Company generates revenue from the sale of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company's headquarters is located in Los Angeles, California. For more information, please visit www.responsegenetics.com.
Forward-Looking Statement Notice
Except for the historical information contained herein, this press release and the statements of representatives of the Company related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company, to provide clinical testing services to the medical community, to continue to strengthen and expand its sales force, to continue to build its digital pathology initiative, to attract and retain qualified management, to continue to strengthen marketing capabilities, to expand the suite of ResponseDX® products, to continue to provide clinical trial support to pharmaceutical clients, to enter into new collaborations with pharmaceutical clients, to enter into areas of companion diagnostics, to continue to execute on its business strategy and operations, to continue to analyze cancer samples and the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, and other statements identified by words such as "project," "may," "could," "would," "should," "believe," "expect," "anticipate," "estimate," "intend," "plan" or similar expressions.
These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.
CONTACT: Investor Relations Contact:
Peter Rahmer
Trout Group
646-378-2973
Company Contact:
Thomas A. Bologna
Chairman & Chief Executive Officer
323-224-3900
Email from RGDX IR
Courtesy of Rhodey
Fast response from Peter Rahmer at IR!!!! Nothing earth shattering from this somewhat canned reply, but I always appreciate when companies respond so quickly to Investor concerns.
*** My personal info has been redacted ****
Thanks for the email. I understand your concerns. The company is still on track for all upcoming milestones that have been stated to date. The Q4/2013 year-end results will be coming around the 3rd week of the month in which the company will provide a thorough update on all the progress being made and speak specifically to 2014 catalysts. I'm sorry that you are frustrated with the short term stock price volatility, but I can assure you that Tom and the team at Response are working tirelessly to fulfill the promise you reference below. We appreciate your long-term support as a shareholder and please don't hesitate to reach out with any questions about the company.
Post this to SHEFF on his board
the circle is about to finally come to a close!
fuckkk been a long 2 months
thoughts on RGDX here?
$RGDX hopefully we see some catalysts start cropping up.
Im thinking there is a grander plan in the works. If earnings where bad they may be pumping with PR's...but no prs so maybe they are good just a thought
they have been dead quiet hopefully this is a good thing and not a bad thing. $RGDX
why talk about catalysts then sell lol? weird bit hopefully we fly now that the flock is out.
http://Insider Buying.com/schedule13d/view/marxe-austin-w-greenhouse-david-m-sc-13ga-2014-02-13-rgdx
200 ma here we come!!! With news 2$ buck chuck (assuming it's good)
need some catalysts to play out soon!
RGDX 1.43 finally moving
Hopefully 200ma
hopefully she pushes past that tomorrow
lets see how she does tomorrow
no kiddin lol
looks better now
starting to shape up
RGDX hope this is reversal time
Reversal time?
http://investor.responsegenetics.com/contactus.cfm
email em and bitch em out for being retards and can't maintain share price. i did lol waiting for response
RGDX 1.23 new low